PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Pitt, Bertram
TI  - Spironolactone Misses Primary Endpoint in TOPCAT
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 21--22
VI  - 14
IP  - 12
4099  - http://mdc.sagepub.com/content/14/12/21.2.short
4100  - http://mdc.sagepub.com/content/14/12/21.2.full
AB  - Spironolactone treatment of heart failure (HF) with preserved ejection fraction (HFpEF) did not significantly reduce cardiovascular death, hospitalization due to HF, or resuscitated cardiac arrest compared with placebo. This article presents updated data from the Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function trial [TOPCAT; Shah SJ et al. Circ Heart Fail 2012].